C4 Therapeutics, Inc. (CCCC)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about C4 Therapeutics, Inc. (CCCC)
Go deeper and ask any question about CCCC
Company Performance
Current Price
as of Sep 17, 2024$6.46
P/E Ratio
N/A
Market Cap
$447.92M
Description
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.
Metrics
Overview
- HQWatertown, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerCCCC
- Price$6.46+1.57%
Trading Information
- Market Cap$447.92M
- Float82.75%
- Average Daily Volume (1m)1,261,647
- Average Daily Volume (3m)1,605,119
- EPS-$1.90
Company
- Revenue$29.38M
- Rev Growth (1yr)350.68%
- Net Income-$17.72M
- Gross Margin82.97%
- EBITDA Margin-161.56%
- EBITDA-$19.40M
- EV$122.22M
- EV/Revenue4.16
- P/EN/A
- P/S15.13